Is the effect of platelet-activating factor ( PAF ) on nasal airway resistance in healthy subjects mediated by nitric oxide?
Topical administration of the NO-synthase inhibitor L-NAME at doses sufficient to decrease NO nasal production does not prevent the PAF-induced increase in NAR, indicating that NO generation in vivo is not involved in the nasal response to PAF.
ULBP1 is prevalently expressed in DN to mod-HCC, but loss of its expression correlates with tumor progression and early recurrence.